PGP - phosphoglycolate phosphatase Gene
Also Known as AUM; G3PP; PGPase
Species: Homo sapiens
Gene Type: protein coding
Gene ID: 283871
About PGP
Cytogenetic location: 16p13.3
Genomic coordinates (GRCh38): 16:2,211,593-2,214,840 (from NCBI)
This gene has 2 transcripts (splice variants), 211 orthologues and 3 paralogues. Broad expression in testis (RPKM 12.7), brain (RPKM 7.6) and 25 other tissues.
Summary
Enables glycerol-3-phosphatase activity and phosphoglycolate Phosphatase activity. Involved in glycerol biosynthetic process; glycerophospholipid metabolic process; and negative regulation of gluconeogenesis. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2022]
PGP Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001042371.3 | NP_001035830.1 | glycerol-3-phosphate phosphatase |
| Molecular Function GO Annotation | Evidence | References | Source |
|---|---|---|---|
| enables glycerol-3-phosphatase activity |
IDA
IDA: Inferred from direct assay
|
26755581 | GOA |
| enables phosphoglycolate phosphatase activity |
IDA
IDA: Inferred from direct assay
|
26755581 | GOA |
| Biological Process GO Annotation | Evidence | References | Source |
|---|---|---|---|
| involved in glycerol biosynthetic process |
IDA
IDA: Inferred from direct assay
|
26755581 | GOA |
| involved in glycerophospholipid metabolic process |
IDA
IDA: Inferred from direct assay
|
26755581 | GOA |
| involved in negative regulation of gluconeogenesis |
IMP
IMP: Inferred from mutant phenotype
|
26755581 | GOA |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
PGP Protein Structure
Hydrolase_6
Hydrolase_6: Haloacid dehalogenase-like hydrolase (31 - 138)
Hydrolase_like
Hydrolase_like: HAD-hyrolase-like (233 - 315)
- 0
- 100
- 200
- 300
- 321 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
glycerol-3-phosphate phosphatase |
|
Related Diseases
| Diseases | Alias | |
|---|---|---|
| Sennetsu Fever |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(22)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-14275 | Verapamil | 99.96% | Yes | |
| HY-A0064 | Verapamil hydrochloride | 99.98% | Yes | |
| HY-10440 | Vismodegib | 99.97% | Yes | |
| HY-B1751 | Quinidine (15% dihydroquinidine) | 98.36% | Unkown | |
| HY-17367 | Atazanavir | 99.13% | Yes | |
| HY-B0777 | Moxidectin | Inhibitor | 99.32% | Yes |
| HY-B1302 | Quinidine hydrochloride monohydrate | 99.97% | Yes | |
| HY-17367A | Atazanavir sulfate | 99.68% | Yes | |
| HY-145574 | Iruplinalkib | Inhibitor | 99.62% | Unkown |
| HY-B1180 | Vinburnine | 99.78% | Unkown | |
| HY-A0064R | Verapamil hydrochloride (Standard) | 99.81% | Unkown | |
| HY-B0168B | Levomilnacipran hydrochloride | 99.95% | Unkown | |
| HY-14275R | Verapamil (Standard) | 99.72% | Unkown | |
| HY-B0501 | Danofloxacin mesylate | Inhibitor | 99.88% | Unkown |
| HY-W001601 | Budipine | Antagonist | 99.41% | Unkown |
| HY-N7120 | Penicillin G procaine hydrate | Inhibitor | 98.85% | Unkown |
| HY-14794A | Levomilnacipran | / | Unkown | |
| HY-B0777R | Moxidectin (Standard) | Inhibitor | / | Unkown |
| HY-B1751A | Quinidine sulfate | / | Unkown | |
| HY-B1751E | Quinidine polygalacturonate | / | Unkown | |
| HY-B1751F | Quinidine gluconic acid | / | Unkown | |
| HY-B1751D | Quinidine sulfate dihydrate | / | Unkown |
Clinical Phase
Bioactive Molecules
(15)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-109566 | Elrelesertib | 99.22% | Phase 3 | |
| HY-15255 | Zosuquidar | Inhibitor | 99.96% | Phase 3 |
| HY-17013A | Dofequidar fumarate | Inhibitor | 98.0% | Phase 3 |
| HY-10550B | Tariquidar dimesylate | Inhibitor | / | Phase 3 |
| HY-106004 | Zamicastat | Inhibitor | 99.93% | Phase 2 |
| HY-14942 | Berubicin | 85.02% | Phase 2 | |
| HY-132189 | Laniquidar | Inhibitor | 99.42% | Phase 2 |
| HY-19642 | Glesatinib | Inhibitor | / | Phase 2 |
| HY-119101 | AZD-5672 | 95.74% | Phase 2 | |
| HY-14942A | Berubicin hydrochloride | 95.08% | Phase 2 | |
| HY-16773 | Vedroprevir | Inhibitor | / | Phase 2 |
| HY-50879 | Elacridar | Inhibitor | 99.66% | Phase 1 |
| HY-108286 | Talinolol | Antagonist | 99.64% | Phase 1 |
| HY-50879R | Elacridar (Standard) | Inhibitor | 97.50% | Phase 1 |
| HY-19405 | UK-224671 | Antagonist | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(186)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-10010 | Ko 143 | Inhibitor | 99.97% | Unkown |
| HY-10550 | Tariquidar | Inhibitor | 99.45% | Yes |
| HY-N6684 | Deoxynivalenol | 99.90% | Unkown | |
| HY-50671 | Zosuquidar trihydrochloride | Inhibitor | 99.50% | Unkown |
| HY-50880 | Elacridar hydrochloride | Inhibitor | 99.93% | Unkown |
| HY-107643 | Reversan | Inhibitor | 99.57% | Unkown |
| HY-10550A | Tariquidar methanesulfonate, hydrate | Inhibitor | 98.55% | Yes |
| HY-13925 | PD0166285 | 99.46% | Unkown | |
| HY-N0217 | Benzoylaconine | 99.92% | Unkown | |
| HY-108694 | γ-Tocotrienol | Inhibitor | 99.73% | Unkown |
| HY-N3584 | Paris saponin VII | 99.84% | Unkown | |
| HY-N1916 | Coniferyl ferulate | 98.73% | Unkown | |
| HY-N0248 | Saikosaponin B2 | 99.98% | Unkown | |
| HY-N2453 | Convallatoxin | 99.72% | Unkown | |
| HY-100750 | Norverapamil hydrochloride | Inhibitor | 99.80% | Unkown |
| HY-N0419 | Quercimeritrin | 99.48% | Unkown | |
| HY-161246 | uPSEM792 | Agonist | 98.02% | Unkown |
| HY-126940 | Furanodiene | 99.83% | Unkown | |
| HY-D1005A25 | Poloxamer 403 (P123) | / | Unkown | |
| HY-19642A | Glesatinib hydrochloride | Inhibitor | 98.01% | Unkown |
| HY-N1941 | Isosinensetin | Inhibitor | 99.90% | Unkown |
| HY-D1005A10 | Poloxamer 184 (L64) | Inhibitor | / | Unkown |
| HY-N0566 | 23-Hydroxybetulinic acid | 99.44% | Unkown | |
| HY-N2103 | Tenacissoside G | 99.64% | Unkown | |
| HY-W009141 | 1-Monopalmitin | 99.89% | Unkown | |
| HY-117738 | Benarthin | Inhibitor | 95.79% | Unkown |
| HY-17013 | Dofequidar | Inhibitor | 99.29% | Unkown |
| HY-A0064S | Verapamil-d3 hydrochloride | 99.57% | Unkown | |
| HY-173162 | GPV0057 | 99.20% | Unkown | |
| HY-N2416 | Taccalonolide A | 99.29% | Unkown | |
| HY-155079 | DZD1516 | Inhibitor | 99.62% | Unkown |
| HY-B0777S | Moxidectin-d3 | Inhibitor | 95.71% | Unkown |
| HY-D1005A23 | Poloxamer 401 (L121) | Inhibitor | / | Unkown |
| HY-D1005A8 | Poloxamer 181 (L61) | Inhibitor | / | Unkown |
| HY-N6015 | Bacopasaponin C | Inhibitor | 99.76% | Unkown |
| HY-119229 | VRT-325 | Modulator | 99.58% | Unkown |
| HY-119823 | PGP-4008 | Inhibitor | 99.26% | Unkown |
| HY-N3028 | Taccalonolide B | Inhibitor | 99.46% | Unkown |
| HY-N6932 | Voacamine | 99.64% | Unkown | |
| HY-RS00048 | ABCB1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-113805 | MC70 | Inhibitor | 99.33% | Unkown |
| HY-N4108 | Hypophyllanthin | Inhibitor | 98.84% | Unkown |
| HY-W035709 | Hydrocinchonine | 98.33% | Unkown | |
| HY-N6748 | Roquefortine C | 98.03% | Unkown | |
| HY-19626 | NSC23925 | Inhibitor | 99.43% | Unkown |
| HY-101791 | P-gp inhibitor 1 | Inhibitor | 98.79% | Unkown |
| HY-132866 | YS-370 | Inhibitor | 98.07% | Unkown |
| HY-155391 | hCA/Wnt/β-catenin-IN-1 | Inhibitor | 99.96% | Unkown |
| HY-176557 | NCI677397 | / | Unkown | |
| HY-W777317 | Elacridar-d4(Major) | / | Unkown | |
| HY-Z15823 | (R)-Verapamil | 98.97% | Unkown | |
| HY-108286A | (-)-Talinolol | 99.26% | Unkown | |
| HY-141425 | NSC73306 | 98.52% | Unkown | |
| HY-162373 | α-Amylase/α-Glucosidase-IN-10 | Inhibitor | / | Unkown |
| HY-110377 | Tariquidar dihydrochloride | Inhibitor | / | Unkown |
| HY-112912 | P-gp modulator 1 | / | Unkown | |
| HY-130244 | BACE1-IN-5 | Inhibitor | / | Unkown |
| HY-128685 | FD 12-9 | Inhibitor | / | Unkown |
| HY-146096 | RMS3 | / | Unkown | |
| HY-146097 | RMS5 | / | Unkown | |
| HY-149053 | OY-101 | Inhibitor | / | Unkown |
| HY-17367S2 | Atazanavir-d9 | / | Unkown | |
| HY-17367S3 | Atazanavir-d5 | / | Unkown | |
| HY-106753 | Tolnapersine | / | Unkown | |
| HY-108286S | (Rac)-Talinolol-d5 | Antagonist | / | Unkown |
| HY-116976 | NSC-57969 | / | Unkown | |
| HY-117593 | NSC 23925B | Inhibitor | / | Unkown |
| HY-118083 | Pentamethoxymorin | Inhibitor | / | Unkown |
| HY-120790 | S 16317 | / | Unkown | |
| HY-121247 | Bromotetrandrine | Inhibitor | / | Unkown |
| HY-123384 | KR30031 | Inhibitor | / | Unkown |
| HY-135328AS | Norverapamil-d7 hydrochloride | Antagonist | 98.86% | Unkown |
| HY-135328S | Norverapamil-d7 | Inhibitor | / | Unkown |
| HY-13774 | WK-X-34 | Inhibitor | / | Unkown |
| HY-13925A | PD0166285 dihydrochloride | / | Unkown | |
| HY-14275S1 | Verapamil-d7 | / | Unkown | |
| HY-144366 | P-gp inhibitor 3 | Inhibitor | / | Unkown |
| HY-144393 | P-gp/BCRP-IN-1 | Inhibitor | / | Unkown |
| HY-146117 | P-gp modulator 2 | Modulator | / | Unkown |
| HY-146118 | P-gp modulator 3 | Modulator | / | Unkown |
| HY-146391 | P-gp inhibitor 4 | Modulator | / | Unkown |
| HY-147758 | BACE1/2-IN-1 | Inhibitor | / | Unkown |
| HY-14794AS | Levomilnacipran-d10 hydrochloride | / | Unkown | |
| HY-149053B | (R)-OY-101 | / | Unkown | |
| HY-149240 | Anticancer agent 108 | Inhibitor | / | Unkown |
| HY-149277 | FM04 | Inhibitor | 99.86% | Unkown |
| HY-149360 | P-gb-IN-1 | Inhibitor | / | Unkown |
| HY-149813 | P-gp inhibitor 14 | Inhibitor | / | Unkown |
| HY-149981 | P-gp inhibitor 13 | Inhibitor | / | Unkown |
| HY-150565 | P-gp inhibitor 5 | Inhibitor | / | Unkown |
| HY-152079 | CYP1B1-IN-3 | Inhibitor | / | Unkown |
| HY-155032 | P-gp inhibitor 15 | Inhibitor | / | Unkown |
| HY-157330 | P-gp inhibitor 16 | / | Unkown | |
| HY-157483 | P-gp inhibitor 18 | Inhibitor | / | Unkown |
| HY-157484 | P-gp inhibitor 19 | Inhibitor | / | Unkown |
| HY-157876 | Anticancer agent 191 | Inhibitor | / | Unkown |
| HY-158236 | ORL1 antagonist 2 | Antagonist | / | Unkown |
| HY-158429 | PROTAC CYP1B1 degrader-2 | / | Unkown | |
| HY-158435 | P-gp inhibitor 23 | Inhibitor | / | Unkown |
| HY-159085 | P-gp inhibitor 24 | Inhibitor | / | Unkown |
| HY-159935 | Top1-IN-2 | Inhibitor | / | Unkown |
| HY-161260 | P-gp inhibitor 20 | Inhibitor | / | Unkown |
| HY-161645 | P-gp modulator-4 | Modulator | / | Unkown |
| HY-161776 | P-gp/CDK2-IN-1 | Inhibitor | / | Unkown |
| HY-162040 | P-gp inhibitor 17 | Inhibitor | / | Unkown |
| HY-162369 | PID-9 | Inhibitor | / | Unkown |
| HY-162396 | P-gp inhibitor 21 | Inhibitor | / | Unkown |
| HY-162447 | P-gp inhibitor 22 | / | Unkown | |
| HY-16265A | JI-101 hydrochloride | Inhibitor | / | Unkown |
| HY-162822 | P-gp modulator-5 | Modulator | / | Unkown |
| HY-163204 | RhQ-DMB | Inhibitor | / | Unkown |
| HY-165491 | R 101933 | Inhibitor | / | Unkown |
| HY-165606 | SB-T-1214 | Inducer | / | Unkown |
| HY-168008 | P-gp inhibitor 25 | Inhibitor | / | Unkown |
| HY-168186 | P-gp inhibitor 26 | Inhibitor | / | Unkown |
| HY-168711 | P-gp inhibitor 27 | Inhibitor | / | Unkown |
| HY-168953 | Lysosomal P-gp targeted agent 1 | / | Unkown | |
| HY-17013D | Dofequidar sesquifumarate | Inhibitor | / | Unkown |
| HY-172365 | P7–2302 | Inhibitor | / | Unkown |
| HY-173182 | Antitumor agent-200 | Inhibitor | / | Unkown |
| HY-173222 | P-gp inhibitor 28 | Inhibitor | / | Unkown |
| HY-173401 | P-gp inhibitor 29 | Inhibitor | / | Unkown |
| HY-17367S4 | Atazanavir-d6 | 99.28% | Unkown | |
| HY-174223 | α-Glucosidase-IN-90 | Inhibitor | / | Unkown |
| HY-174324 | VEGFR-2/P-gp-IN-1 | / | Unkown | |
| HY-175206 | P-gp-IN-30 | Inhibitor | / | Unkown |
| HY-175522 | P-gp-IN-31 | / | Unkown | |
| HY-175838 | P-gp-IN-32 | Inhibitor | / | Unkown |
| HY-176193 | P-gp modulator-7 | Inhibitor | / | Unkown |
| HY-176421 | PROTAC PI3K/110β degrader-1 | / | Unkown | |
| HY-17648 | MBL-II-141 | Inhibitor | / | Unkown |
| HY-178349 | P-gp inhibitor 30 | / | Unkown | |
| HY-178466 | Tubulin polymerization/P-gp-IN-1 | / | Unkown | |
| HY-179683 | MRP1-IN-2 | Inhibitor | / | Unkown |
| HY-180282 | P-gp-IN-33 | Inhibitor | / | Unkown |
| HY-181252 | P-gp-IN-35 | Inhibitor | / | Unkown |
| HY-181773 | P-gp-IN-36 | Inhibitor | / | Unkown |
| HY-181889 | KRAS G12C-IN-75 | Inhibitor | / | Unkown |
| HY-182753 | Tubulin-IN-66 | / | Unkown | |
| HY-183143 | Lss-11 | / | Unkown | |
| HY-184469 | DVL1/P-gp-IN-1 | / | Unkown | |
| HY-184489 | PGP/FSP1-IN-1 | / | Unkown | |
| HY-A0064S1 | Verapamil-d6 hydrochloride | / | Unkown | |
| HY-B0168BS | Levomilnacipran-d5 hydrochloride | / | Unkown | |
| HY-B1751S | Quinidine-d3 | / | Unkown | |
| HY-B1751S1 | Quinidine-13C, d2 hydrochloride | / | Unkown | |
| HY-D1005A9 | Poloxamer 183 (L63) | Inhibitor | / | Unkown |
| HY-N10342 | Cajanol | / | Unkown | |
| HY-N13157 | 11α-O-Benzoyl-12β-O-acetyltenacigenin B | Inhibitor | / | Unkown |
| HY-N144114 | P-gp inhibitor 2 | Inhibitor | / | Unkown |
| HY-N15636 | Coccinine | Inhibitor | / | Unkown |
| HY-N16684 | Clausarin | Inhibitor | / | Unkown |
| HY-N6748S | Roquefortine C-13C22 | / | Unkown | |
| HY-N7917 | Tenacigenoside A | / | Unkown | |
| HY-RS10394 | PGP Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS10395 | PGPEP1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W009141S | 1-Monopalmitin-d31 | / | Unkown | |
| HY-W115674 | Quinidine hydrochloride | / | Unkown | |
| HY-W140488 | 1,2-Didecanoyl-sn-glycero-3-phosphoethanolamine | / | Unkown | |
| HY-W286423 | L-Pyroglutamic acid 7-amido-4-methylcoumarin | Substrate | / | Unkown |
| HY-W700684 | N-Didesmethyl Loperamide | / | Unkown | |
| HY-107197 | 8-Prenylchrysin | Inhibitor | / | Unkown |
| HY-109566R | Elrelesertib (Standard) | / | Unkown | |
| HY-111175 | IG-105 | / | Unkown | |
| HY-123934 | VU6007477 | Modulator | / | Unkown |
| HY-129698 | MS-073 | Inhibitor | / | Unkown |
| HY-135328 | Norverapamil | Inhibitor | / | Unkown |
| HY-13646B | Encequidar hydrochloride | Inhibitor | / | Unkown |
| HY-14275S | Verapamil-d3 | / | Unkown | |
| HY-14275S2 | Verapamil-d6 | / | Unkown | |
| HY-164585 | P-gp modulator-6 | Modulator | / | Unkown |
| HY-169782 | CJZ3 | Inhibitor | / | Unkown |
| HY-17367S5 | Atazanavir-d24 | / | Unkown | |
| HY-179612 | SARS-CoV-2 3CLpro-IN-34 | Inhibitor | / | Unkown |
| HY-B1180A | Vinburnine phosphate | / | Unkown | |
| HY-N7305 | Jatrophane 5 | Inhibitor | / | Unkown |
| HY-N7332 | Pepluanin A | Inhibitor | / | Unkown |
| HY-RS17045 | Pgp Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23489 | Pgp Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W001601A | Budipine hydrochloride | Antagonist | / | Unkown |
| HY-W035709R | Hydrocinchonine (Standard) | / | Unkown | |
| HY-W699430 | Norverapamil-d6 hydrochloride | Inhibitor | / | Unkown |
| HY-W705354 | Vismodegib-d4 | / | Unkown | |
| HY-W716916 | Vismodegib-d7 | / | Unkown | |
| HY-W854295 | Phosphatidylinositol-1,2-dioctanoyl sodium | Inhibitor | / | Unkown |
| HY-U00247 | MCI826 | Agonist | / | Unkown |
Orthologs Information
| Species | Symbol | Source | ID |
|---|---|---|---|
| Bos taurus | PGP | VGNC | VGNC:32798 |
| Macaca mulatta | PGP | VGNC | VGNC:104745 |
| Mus musculus | PGP | MGD | MGI:1914328 |
| Felis catus | PGP | VGNC | VGNC:80673 |
| Rattus norvegicus | PGP | RGD | RGD:1307773 |
| Others | PGP | NCBI |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service